Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 52-Week Low After Analyst Downgrade

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price reached a new 52-week low during trading on Tuesday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The company traded as low as $29.00 and last traded at $29.00, with a volume of 24,865 shares traded. The stock had previously closed at $41.92.

A number of other equities research analysts have also recently issued reports on SUPN. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings lowered shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday. Jefferies Financial Group began coverage on shares of Supernus Pharmaceuticals in a report on Wednesday. They set a “strong-buy” rating for the company. Finally, Piper Sandler began coverage on shares of Supernus Pharmaceuticals in a report on Wednesday. They set an “overweight” rating and a $47.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $63.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SUPN. Mystic Asset Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $1,181,000. Bank of America Corp DE acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $28,887,000. BlackRock Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $434,871,000. The Manufacturers Life Insurance Company bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $1,298,000. Finally, Great Lakes Advisors LLC bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $1,386,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Supernus Pharmaceuticals Trading Up 0.2%

The business has a 50 day moving average of $41.74 and a 200-day moving average of $47.04. The firm has a market capitalization of $3.33 billion, a P/E ratio of 7.88 and a beta of 0.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The company had revenue of $208.60 million during the quarter, compared to analyst estimates of $217.56 million. During the same quarter last year, the company earned ($0.80) EPS. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 3.66 EPS for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The company also recently declared a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be paid a $8.13 dividend.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.